ACTRN12613000973718已完成不适用
Evaluation of the Pharmacokinetics of IPX231 (L0007, C0001) in Healthy Subjects
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 20
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomised controlled trial
- 主要目的
- Treatment
- 盲法
- Open (masking not used)
入排标准
- 年龄范围
- 18 Years 至 45 Years（—）
- 性别
- All
入选标准
- •Healthy adult subjects between 18 years and 45 years of age inclusive at the time of informed consent.
排除标准
- •Presence of a clinically significant disorder, as determined by the Investigator, involving bleeding or hematologic or cardiovascular system abnormalities, acute infections, respiratory, renal, gastrointestinal, immunologic, hepatic, reproductive, endocrine, or neurologic system(s); or psychiatric disease; or oral trauma or disease.
研究者
相似试验
已完成
1 期
Evaluation of the Pharmacokinetics of IPX237 Formulations in Healthy VolunteersDepressionMental Health - DepressionACTRN12613001097730Impax Pharmaceuticals, A Division of Impax Laboratories, Inc.24
撤回
1 期
Evaluation of the pharmacokinetics and safety of multiple once-daily doses of IPX233 in healthy adult volunteersAttention Deficit Hyperactivity Disorder (ADHA)Neurological - Other neurological disordersMental Health - Other mental health disordersACTRN12614000518662Impax Laboratories, Inc20
已完成
1 期
Evaluation of the Pharmacokinetics and Safety of Dihydroergotamine Administered Via Two Intranasal Delivery DevicesMigraineACTRN12614000330640Impax Laboratories, Inc14
已完成
1 期
Evaluation of the Pharmacokinetics of Sublingual IPX237 in Healthy VolunteersDepressionACTRN12614000444684Impax Pharmaceuticals,A Division of Impax Laboratories, Inc.24
已完成
不适用
Pharmacokinetics of IPX203Neurological - Parkinson's diseaseParkinson's DiseaseACTRN12613001057774Impax Laboratories, Inc. Acting through its Impax Pharmaceuticals Division20